Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
3801
Organogenesis Holdings
ORGO
$132M
| $243K | ﹤0.01% |
177,643
+15,182
| +9% | +$29.8K |
2019 Q1
30 quarters
|
|
3802
Broadwind
BWEN
$71.7M
| $243K | ﹤0.01% |
+58,050
| New | +$259K |
2026 Q3
0 quarters
|
|
3803
Tootsie Roll Industries
TR
$2.9B
| $243K | ﹤0.01% |
6,458
-23,659
| -79% | -$927K |
2013 Q2
53 quarters
|
|
3804
Sionna Therapeutics
SION
$170M
| $242K | ﹤0.01% |
46,005
+39,510
| +608% | +$907K |
2025 Q2
5 quarters
|
|
3805
Gyre Therapeutics
GYRE
$472M
| $242K | ﹤0.01% |
32,975
+29,747
| +922% | +$198K |
2024 Q2
9 quarters
|
|
3806
JBS N.V.
JBS
$13.2B
| $241K | ﹤0.01% |
21,387
-21,983
| -51% | -$281K |
2025 Q3
4 quarters
|
|
3807
Ascent Industries
ACNT
$122M
| $241K | ﹤0.01% |
17,095
-194
| -1% | -$2.93K |
2024 Q4
7 quarters
|
|
3808
Methode Electronics
MEI
$457M
| $241K | ﹤0.01% |
17,459
+11,989
| +219% | +$185K |
2013 Q2
53 quarters
|
|
3809
Immix Biopharma
IMMX
$716M
| $240K | ﹤0.01% |
23,047
-30,009
| -57% | -$340K |
2025 Q4
3 quarters
|
|
3810
Corbus Pharmaceuticals
CRBP
$78.1M
| $240K | ﹤0.01% |
35,144
+27,142
| +339% | +$251K |
2024 Q1
10 quarters
|
|
3811
Riley Exploration Permian
REPX
$933M
| $240K | ﹤0.01% |
5,988
+3,574
| +148% | +$134K |
2022 Q1
18 quarters
|
|
3812
Greenfire Resources
GFR
$1.85B
| $239K | ﹤0.01% |
42,371
+40,395
| +2,044% | +$252K |
2025 Q4
3 quarters
|
|
3813
PUT
Global X Uranium ETF
URA
$4.66B
| $239K | ﹤0.01% |
+6,000
| New | +$257K |
2026 Q3
0 quarters
|
|
3814
SoundThinking
SSTI
$109M
| $238K | ﹤0.01% |
28,677
+5,708
| +25% | +$41K |
2018 Q1
34 quarters
|
|
3815
LSB Industries
LXU
$804M
| $238K | ﹤0.01% |
24,369
+11,124
| +84% | +$120K |
2022 Q2
17 quarters
|
|
3816
XMAX Inc
XMAX
$445M
| $238K | ﹤0.01% |
27,580
-64,052
| -70% | -$562K |
2026 Q1
2 quarters
|
|
3817
Alto Ingredients
ALTO
$299M
| $237K | ﹤0.01% |
64,231
+8,070
| +14% | +$36.4K |
2022 Q1
18 quarters
|
|
3818
MacroGenics
MGNX
$153M
| $237K | ﹤0.01% |
61,312
+11,482
| +23% | +$47.4K |
2019 Q1
30 quarters
|
|
3819
Hemab Therapeutics
COAG
$1.85B
| $236K | ﹤0.01% |
7,664
+6,653
| +658% | +$292K |
2026 Q2
1 quarter
|
|
3820
Global X MLP & Energy Infrastructure ETF
MLPX
$3.55B
| $236K | ﹤0.01% |
3,373
+3,340
| +10,121% | +$249K |
2025 Q4
3 quarters
|
|
3821
Critical Metals Corp
CRML
$1.12B
| $235K | ﹤0.01% |
32,406
-520,498
| -94% | -$3.7M |
2024 Q2
9 quarters
|
|
3822
Landmark Bancorp
LARK
$198M
| $235K | ﹤0.01% |
7,583
+1,507
| +25% | +$47.7K |
2025 Q2
5 quarters
|
|
3823
Tenax Therapeutics
TENX
$77.9M
| $235K | ﹤0.01% |
124,205
+116,151
| +1,442% | +$875K |
2026 Q1
2 quarters
|
|
3824
Nextdoor Holdings, Inc. Class A Common Stock
NXDR
$781M
| $234K | ﹤0.01% |
96,162
+50,546
| +111% | +$120K |
2023 Q2
13 quarters
|
|
3825
Hesai Group
HSAI
$2.34B
| $234K | ﹤0.01% |
+14,646
| New | +$249K |
2026 Q3
0 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.